false
0000070487
0000070487
2023-11-07
2023-11-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 7, 2023
_______________________________________________________________________________
National Research Corporation
(Exact name of registrant as specified in its charter)
Delaware
|
001-35929
|
47-0634000
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
1245 Q Street, Lincoln, Nebraska
|
68508
|
(Address of principal executive offices)
|
(Zip Code)
|
(402) 475-2525
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
$.001 Par Value Common Stock |
NRC |
The NASDAQ Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
Emerging growth company ☐
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.02
|
Results of Operations and Financial Condition.
|
|
|
|
On November 7, 2023, National Research Corporation, a Delaware corporation (the "Company"), issued a press release announcing its financial and operating results for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.
On November 8, 2023, the Company held a conference call and online Web simulcast in connection with the Company’s announcement of its earnings for the third quarter ended September 30, 2023. A copy of the script for such conference call and simulcast is furnished as Exhibit 99.2 to this report. An archive of such conference call and simulcast and the related question and answer session will be available online at https://events.q4inc.com/attendee/533804877.
|
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
(d)
|
Exhibits.
|
|
|
|
|
EXHIBIT
NUMBER
|
EXHIBIT DESCRIPTION
|
|
|
|
|
99.1
|
|
|
99.2
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
|
|
The information contained in Items 2.02 and 9.01 of this report and the exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
|
|
|
The information in Items 2.02 and 9.01 of this report and the exhibits hereto may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements are made based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results or events may differ from those anticipated by forward-looking statements. Please refer to the paragraph at the end of the attached press release and various disclosures by the Company in its press releases, stockholder reports, and filings with the Securities and Exchange Commission for information concerning risks, uncertainties, and other factors that may affect future results.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NATIONAL RESEARCH CORPORATION
|
|
(Registrant)
|
|
|
|
|
Date: November 8, 2023
|
By:
|
/s/ Kevin R. Karas
|
|
|
Kevin R. Karas
|
|
|
Senior Vice President Finance, Chief Financial Officer, Treasurer and Secretary
|
EXHIBIT INDEX
EXHIBIT
NUMBER
|
EXHIBIT DESCRIPTION
|
|
|
99.1
|
National Research Corporation press release announcing its financial and operating results for the third quarter ended September 30, 2023.
|
99.2
|
National Research Corporation script for the conference call and online Web simulcast held November 8, 2023.
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
Exhibit 99.1
|
1245 Q Street, Lincoln, NE 68508
P: 1 800 388 4264 | F: 402 475 9061
nrchealth.com
|
Contact: |
Kevin R. Karas |
|
Chief Financial Officer |
|
402-475-2525 |
NATIONAL RESEARCH CORPORATION ANNOUNCES
THIRD QUARTER 2023 RESULTS
LINCOLN, Nebraska (November 7, 2023) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2023.
Regarding the Company’s 2023 third quarter, Kevin Karas, Chief Financial Officer, said, “New sales increased compared to the third quarter of 2022, supported by growth in our Human Understanding Program, with adoption by 91 healthcare organizations as of September 30, 2023. While building our sales pipeline, we are also highly focused on controlling costs in an inflationary environment. We have realized sequential quarterly operating margin improvement in the last two quarters and will continue to emphasize returning to our historical operating margins.”
Mr. Karas continued: “From a capital standpoint, NRC remains well-positioned to execute the entire range of capital allocation alternatives, including funding innovation and growth investments, shareholder dividends and share repurchases. At September 30, 2023, the Company had approximately $20 million of net debt and $25 million available on its revolving line of credit after funding $3.7 million for innovation and growth, $27.5 million for dividend payments, and $310,000 for share repurchases during the quarter.”
Diluted earnings per share decreased to $0.32 for the quarter ended September 30, 2023, from diluted earnings per share of $0.33 for the quarter ended September 30, 2022.
© NRC Health
NRC Announces Third Quarter 2023 Results
Page 2
November 7, 2023
A live simulcast of National Research Corporation’s 2023 third quarter conference call will be available online at https://events.q4inc.com/attendee/533804877 November 8, 2023, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email info@nrchealth.com, or visit www.nrchealth.com.
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” “focus,” “will,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022 and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
© NRC Health
NRC Announces Third Quarter 2023 Results
Page 3
November 7, 2023
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
|
|
Three months ended
September 30
|
|
|
Nine months ended
September 30
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$ |
37,945 |
|
|
$ |
37,691 |
|
|
$ |
110,579 |
|
|
$ |
113,424 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct
|
|
|
14,633 |
|
|
|
14,524 |
|
|
|
42,222 |
|
|
|
43,062 |
|
Selling, general and administrative
|
|
|
11,802 |
|
|
|
10,762 |
|
|
|
35,552 |
|
|
|
32,159 |
|
Depreciation and amortization
|
|
|
1,555 |
|
|
|
1,296 |
|
|
|
4,469 |
|
|
|
3,902 |
|
Total operating expenses
|
|
|
27,990 |
|
|
|
26,582 |
|
|
|
82,243 |
|
|
|
79,123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
9,955 |
|
|
|
11,109 |
|
|
|
28,336 |
|
|
|
34,301 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
256 |
|
|
|
15 |
|
|
|
779 |
|
|
|
34 |
|
Interest expense
|
|
|
(160 |
)
|
|
|
(288 |
)
|
|
|
(594 |
)
|
|
|
(923 |
)
|
Other, net
|
|
|
(12 |
)
|
|
|
11 |
|
|
|
(27 |
)
|
|
|
(69 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
84 |
|
|
|
(262 |
)
|
|
|
158 |
|
|
|
(958 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
10,039 |
|
|
|
10,847 |
|
|
|
28,494 |
|
|
|
33,343 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
2,163 |
|
|
|
2,549 |
|
|
|
6,381 |
|
|
|
8,184 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$ |
7,876 |
|
|
$ |
8,298 |
|
|
$ |
22,113 |
|
|
$ |
25,159 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share of Common Stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic Earnings Per Share
|
|
$ |
0.32 |
|
|
$ |
0.34 |
|
|
$ |
0.90 |
|
|
$ |
1.01 |
|
Diluted Earnings Per Share
|
|
$ |
0.32 |
|
|
$ |
0.33 |
|
|
$ |
0.89 |
|
|
$ |
1.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares and share equivalents outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
24,560 |
|
|
|
24,716 |
|
|
|
24,574 |
|
|
|
25,014 |
|
Diluted
|
|
|
24,695 |
|
|
|
24,847 |
|
|
|
24,715 |
|
|
|
25,147 |
|
© NRC Health
NRC Announces Third Quarter 2023 Results
Page 4
November 7, 2023
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except share amounts and par value)
|
|
September 30,
2023
|
|
|
December 31,
2022
|
|
Assets
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
3,828 |
|
|
$ |
25,026 |
|
Accounts receivable, net
|
|
|
14,467 |
|
|
|
14,461 |
|
Other current assets
|
|
|
6,448 |
|
|
|
4,229 |
|
Total current assets
|
|
|
24,743 |
|
|
|
43,716 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
25,589 |
|
|
|
17,248 |
|
Goodwill
|
|
|
61,614 |
|
|
|
61,614 |
|
Other, net
|
|
|
8,190 |
|
|
|
7,883 |
|
Total assets
|
|
$ |
120,136 |
|
|
$ |
130,461 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Current portion of notes payable
|
|
$ |
4,665 |
|
|
$ |
4,491 |
|
Line of credit
|
|
|
5,000 |
|
|
|
-- |
|
Accounts payable and accrued expenses
|
|
|
6,027 |
|
|
|
5,136 |
|
Accrued compensation
|
|
|
5,029 |
|
|
|
4,551 |
|
Deferred revenue
|
|
|
16,238 |
|
|
|
15,198 |
|
Dividends payable
|
|
|
2,947 |
|
|
|
2,956 |
|
Other current liabilities
|
|
|
899 |
|
|
|
1,085 |
|
Total current liabilities
|
|
|
40,805 |
|
|
|
33,417 |
|
|
|
|
|
|
|
|
|
|
Notes payable, net of current portion and unamortized debt issuance costs
|
|
|
14,164 |
|
|
|
17,690 |
|
Other non-current liabilities
|
|
|
7,295 |
|
|
|
7,321 |
|
Total liabilities
|
|
|
62,264 |
|
|
|
58,428 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued
|
|
|
-- |
|
|
|
-- |
|
Common stock, $0.001 par value; authorized 110,000,000 shares, issued 30,956,479 in 2023 and 30,922,181 in 2022, outstanding 24,562,068 in 2023 and 24,628,173 in 2022
|
|
|
31 |
|
|
|
31 |
|
Additional paid-in capital
|
|
|
176,714 |
|
|
|
175,453 |
|
Retained earnings (accumulated deficit)
|
|
|
(36,482 |
)
|
|
|
(25,184 |
)
|
|
|
|
|
|
|
|
|
|
Treasury stock
|
|
|
(82,391 |
)
|
|
|
(78,267 |
)
|
Total shareholders’ equity
|
|
|
57,872 |
|
|
|
72,033 |
|
Total liabilities and shareholders’ equity
|
|
$ |
120,136 |
|
|
$ |
130,461 |
|
© NRC Health
Exhibit 99.2
Kevin:
Thank you, ___________, and welcome everyone to National Research Corporation’s 2023 third quarter earnings call. My name is Kevin Karas, the company’s CFO, and joining me on the call today is Linda Stacy, our Vice President of Finance.
Before we continue, I would ask Linda to review conditions related to any forward-looking statements that may be made as part of today’s call. Linda.
Linda:
Thank you, Kevin.
This conference call includes forward-looking statements related to the Company that involve risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the facts that could affect the Company's future results, please see the Company's filings with the Securities and Exchange Commission. With that, I’ll turn it back to you, Kevin.
Kevin:
Thanks, Linda, and again, welcome everyone.
This quarter was a good start on our plan to accelerate revenue growth and expand margins over the coming quarters. We have seen sales and margin improving sequentially the past two quarters with only partial implementation of the plan. I will cover three topics to set the stage for where we are headed before Linda covers the financial metrics.
First, new sales. NRC Health is a leader in helping healthcare providers improve their patient experience on an individualized basis, using decades of benchmarking and our unique ability to translate data into actionable advice. Our Human Understanding Program, released in the second quarter of 2022, has become widely accepted in the market, with 91 healthcare provider systems adopting HU, 18% of which were from new logos. Contract value growth for Human Understanding Program adoption by existing clients is averaging 13%, which is in line with results from the successful rollout of our Real-time solution several years ago. These results were without the benefit of a fully developed sales force.
To capitalize on growing demand, we have increased the size of our sales force by 19% since the beginning of the year and expect to continue to add experienced personnel in this area. The expansion of sales and marketing resources has been successful in building our sales pipeline and producing two consecutive quarters of double-digit sales growth compared to the prior year. We expect to see the results of these efforts in revenue and TRCV in future periods.
Second, margin expansion. While increasing our sales force, we reduced the number of non-sales personnel. On a net basis, we have decreased the full-time equivalent number of associates by 11% at the end of the third quarter 2023 compared to the end of third quarter 2022. Most of the decrease occurred during the third quarter of 2023, and the related cost reduction has not yet been fully reflected. We expect to see the results of these efforts in revenue per associate and operating margin in future periods.
Third, we are highly cognizant of our clients’ desire for solutions across multiple patient, customer, and employee experiences. With our continued product development and partner alliances, we are expanding our product offerings to take advantage of a much larger existing total addressable market while gaining market share in our core patient experience market.
With that, let me turn the call back over to Linda to review our financial performance and then open the call to your questions.
Linda
Thank you, Kevin.
Revenue for the third quarter 2023 increased slightly compared to the third quarter of 2022.
We ended the quarter with $144.3 million in TRCV. Our TRCV metric represents the total revenue projected under all renewable contracts for their respective next annual renewal periods, assuming no upsells, downsells, price increases, or cancellations, measured as of the most recent quarter end.
Operating income decreased by 10% for the third quarter of 2023 compared to the third quarter of 2022, primarily due to growth in certain costs exceeding revenue growth. Increased investments were made in marketing expenses of $343,000 to expand brand recognition and support sales development and additional cyber security and other software services of $292,000. In addition, we incurred $661,000 of expense in non-recurring state tax incentive adjustments.
The effective tax rate in the third quarter of 2023 was 22% compared to 23% in 2022, primarily due to lower state income taxes of $313,000 partially offset by decreased tax benefits of $138,000 from the exercise of share-based compensation awards.
Operating margin grew by 0.3% over the second quarter of 2023 due to revenue growth outpacing operating expense growth. The workforce reductions and other cost alignment changes implemented during the quarter will enable continued margin improvement in future quarters.
The Company remains well positioned to execute the entire range of capital allocation alternatives, including funding innovation and growth investments, shareholder dividends and share repurchases. At September 30, 2023, the Company had approximately $20 million in net debt and $25 million available on the line of credit after funding $3.7 million for innovation and growth, $27.5 million for dividend payments, and $310,000 for share repurchases in the third quarter.
That concludes my comments for this morning. I’ll now turn the call back to Kevin.
Kevin
Thank you, Linda.
This completes our prepared remarks, so operator I will now ask you to open the call to any questions.
Closing Statement – Kevin
Thank you for your time today. We look forward to sharing our results again next quarter.
v3.23.3
Document And Entity Information
|
Nov. 07, 2023 |
Document Information [Line Items] |
|
Entity, Registrant Name |
National Research Corporation
|
Document, Type |
8-K
|
Document, Period End Date |
Nov. 07, 2023
|
Entity, Incorporation, State or Country Code |
DE
|
Entity, File Number |
001-35929
|
Entity, Tax Identification Number |
47-0634000
|
Entity, Address, Address Line One |
1245 Q Street
|
Entity, Address, City or Town |
Lincoln
|
Entity, Address, State or Province |
NE
|
Entity, Address, Postal Zip Code |
68508
|
City Area Code |
402
|
Local Phone Number |
475-2525
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock
|
Trading Symbol |
NRC
|
Security Exchange Name |
NASDAQ
|
Entity, Emerging Growth Company |
false
|
Amendment Flag |
false
|
Entity, Central Index Key |
0000070487
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
National Research (NASDAQ:NRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
National Research (NASDAQ:NRC)
Historical Stock Chart
From Sep 2023 to Sep 2024